JOINT  WORKSHOP  SERIES

Screenshot (23).png

Workshop 1: Neurodegenerative Disease & Mitochondrial Function assessment

September 24, 2021

9:30 -11:30am EST/2:30- 4:30pm UK
(full agenda and speaker details below)

 

Workshop 2: Neuropsychiatry & Mitochondrial Function assessment

October 29, 2021

9:30 -11:30am EST/2:30- 4:30pm UK

 

UK Clinical Training Workshop: A patient perspective - how to diagnose mitochondrial dysfunction in the brain

November 26, 2021

8:30 -9:30am & 11:00 - 12:00-pm EST 1:30- 2:30pm & 4:00 - 5:00 pm UK

M I T O C H O N D R I A L   &   B R A I N   I N A G U R A L   W O R K S H O P:

 Focus on Neurodegenerative Diseases

 

September  24 , 2021

9:30 - 11:00 am EST /2:30 - 4:00 pm UK

 

AGENDA

*times shown in EST

9:30am - 9:40am
9:40am - 10:00am
10:00am - 10:20am
10:20am - 10:40am
10:40am - 11:00am
11:00am - 11:30am

Welcome Remarks:

Ana Andreazza, Mitochondrial Innovation Initiative

Grainne Gorman, Wellcome Centre Mitochondrial Research

 

Graham Collingridge,

Director Tanz Centre Alzheimer's Disease

 

Daniel Erskine,

Alzheimer’s Research UK Fellow Wellcome Centre for Mitochondrial Research, Newcastle University

 

Suneil Kalia,

Scientist, Krembil Research Institute Parkinson's Disease

 

Amy Reeve, Research UK Fellow

Wellcome Centre for Mitochondrial Research, Newcastle University

 

Panel Discussion with Moderator - Dr. Sandra Black, Senior Scientist,

Sunnybrook Research Institute Remarks & Q&A

MODERATOR
Screenshot (24).png

Sandra Black, OC, O.Ont., MD, FRSC

Senior Scientist Sunnybrook Health Sciences Centre

Sandra E Black, O.C., O.Ont., Hon.DSc.,MD, FRCP(C), FRSC is an internationally renowned cognitive and stroke neurologist, who is a Professor of Medicine (Neurology) in the Department of Medicine. Dr. Black is the Sunnybrook Site Director of the Heart & Stroke Foundation Canadian Partnership for Stroke Recovery, a national network dedicated to improving stroke recovery, and was Executive Director of the Toronto Dementia Research Alliance, a collaboration of memory clinic programs across UofT academic hospitals from 2012-20.

 

She was named to the Order of Ontario in 2011. Dr. Black has also been appointed as an Officer of the Order of Canada in 2015 “for contributing to improved diagnosis and treatment of vascular dementia, Alzheimer’s disease and stroke.” Dr. Black also received the SBCN’s Lifetime Achievement Award in 2020.

SPEAKERS
Screenshot (26).png

Prof. Graham Collingridge FRS, CBE

Director, Tanz Centre for Research in Neurodegenerative Diseases

Senior Investigator Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital

A leading neuroscientist, Professor Collingridge’s research focuses on the mechanisms of synaptic plasticity in health and disease, in particular, understanding synaptic plasticity in molecular terms and how pathological alterations in these processes may lead to major disorders, such as Alzheimer’s disease. Professor Collingridge has won several prizes including the Sharpey-Shafer Prize of the Physiological Society, the Gaddam Memorial Prize of the British Pharmacological Society, and the Feldberg Prize. Professor Collingridge currently is the Director for Tanz Centre for Research in Neurodegenerative Diseases at the University of Toronto.

Screenshot (27).png

Dr. Daniel Erskine Alzheimer’s Research UK Fellow

Wellcome Centre for Mitochondrial Research Newcastle University

Dr. Daniel Erskine is an Alzheimer’s Research UK Fellow at the Wellcome Centre for Mitochondrial Research at Newcastle University, where he leads a research programme dedicated to understanding why Lewy bodies form in some cells but not others, why some neurons are vulnerable to neurodegeneration, and why neurons vulnerable to neurodegeneration are not always those vulnerable to Lewy body formation. In particular, he is interested in the role of mitochondria in cellular vulnerability and Lewy body formation and uses a combination of post-mortem brain tissue and organotypic human cortical tissue cultures from neurosurgical patients to study these relationships.

Screenshot (28).png

Dr. Suneil Kalia Scientist, Krembil Research Institute,

University Health Network

Dr. Kalia is a graduate of the MD/PhD program at the University of Toronto, where he entered the neurosurgery residency program in 2006. During his PhD he discovered novel molecular targets which contribute to the degeneration of dopaminergic neurons in Parkinson's disease.

 

From 2012-13, Dr. Kalia completed a clinical fellowship in functional and stereotactic neurosurgery at Toronto Western Hospital, and was recruited to the Division of Neurosurgery with a staff appointment at Toronto Western Hospital. Currently, he is appointed as an Assistant Professor in the Department of Surgery at the University of Toronto. His research laboratory focuses on understanding molecular mechanisms of protein homeostasis in neurodegeneration and on establishing model systems to study protein function in neurodegenerative disease.

Screenshot (38).png

Dr. Amy Reeve Research Fellow

Wellcome Centre for Mitochondrial Research, Newcastle University

Amy Reeve, PhD, is a research fellow within the Wellcome Centre. Her research career has focused on understanding the contribution of mitochondrial dysfunction to Parkinson’s disease, with a particular focus on the impact of mitochondrial dysfunction and its role in the loss of substantia nigra (SN) neurons. Her primary research models are human post mortem tissue and induced pluripotent stem cells. Amy was the recipient of a Parkinson’s UK Fellowship and is a renowned expert on mitochondrial dysfunction within the SN. Amy is also passionate science communicator and the Faculty Co-Director for Equality, Diversity and Inclusion, FMS, Newcastle University.

Screenshot (23).png